Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krina Patel

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Bone Marrow Transplantation|November 18, 2018
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugsLohith Gowda, Mithun Shah, Ifra Badar, et al.
Transplantation and Cellular Therapy|January 21, 2023
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution ExperienceTaxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, et al.
American Journal of Hematology|July 16, 2016
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplantSameh Gaballa, Rima M Saliba, Samer Srour, et al.
The Lancet. Haematology|May 20, 2017
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalanYago Nieto, Benigno C Valdez, Sai R Pingali, et al.
British Journal of Haematology|January 24, 2021
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapiesElisabet E Manasanch, David Berrios, Eric Fountain, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Haematologica|January 11, 2020
New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicityAdnan Elhammali, Behrang Amini, Ethan B Ludmir, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Bone Marrow Transplantation|November 18, 2018
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugsLohith Gowda, Mithun Shah, Ifra Badar, et al.
Transplantation and Cellular Therapy|January 21, 2023
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution ExperienceTaxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, et al.
American Journal of Hematology|July 16, 2016
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplantSameh Gaballa, Rima M Saliba, Samer Srour, et al.
The Lancet. Haematology|May 20, 2017
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalanYago Nieto, Benigno C Valdez, Sai R Pingali, et al.
British Journal of Haematology|January 24, 2021
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapiesElisabet E Manasanch, David Berrios, Eric Fountain, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Haematologica|January 11, 2020
New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicityAdnan Elhammali, Behrang Amini, Ethan B Ludmir, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Pageof 8